

July 25, 2025

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor
Plot No. C1, 'G' Block, Bandra-Kurla Complex
Bandra (East), Mumbai 400 051.

BSE Limited
Corporate Relationship Department
Floor
25, P.J. Towers
Dalal Street
Mumbai 400 001.

Symbol: RPGLIFE

Scrip code: 532983

Dear Sir/Madam,

Sub: Outcome of Board Meeting of the Company held on July 25, 2025.

In terms of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at its meeting held on Friday, July 25, 2025 inter-alia considered and unanimously approved the following agenda items:

1. Unaudited Financial Results:

The Unaudited Financial Results along with Limited Review Report of the Statutory Auditors thereon are enclosed herewith in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

2. Revision in the Policy for Determination of Materiality of Events:

Revision in the policy for Determination of Materiality of Events in accordance with the amended SEBI (Listing Obligations and Disclosure Requirements), 2015. The aforesaid amended policy shall be made available on the Company's website at www.rpglifesciences.com/policies

The meeting commenced at 03:00 p.m. and concluded at 6.00 p.m.

Kindly take the same on record.

Thanking you,

Yours faithfully,
For RPG Life Sciences Limited

Rajesh Shirambekar
Head – Legal & Company Secretary
Encl.- as above

Independent Auditor's Review Report on the Quarterly Unaudited Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**Review Report to
The Board of Directors
RPG Life Sciences Limited**

1. We have reviewed the accompanying statement of unaudited financial results of RPG Life Sciences Limited (the "Company") for the quarter ended June 30, 2025 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S R B C & C O L L P

Chartered Accountants

ICAI Firm Registration Number: 324982E/E300003**per Aruna Kumaraswamy**

Partner

Membership Number: 219350

UDIN: 25219350BMMACF6070

Place: Mumbai

Date: July 25, 2025



STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2025

Particulars	(Rs. in Lakhs)			
	Quarter ended			Year ended
	30-06-2025	31-03-2025	30-06-2024	31-03-2025
	Unaudited	Audited (Refer note 4)	Unaudited	Audited
1 Revenue from Operations	16,892	14,309	16,542	65,343
2 Other Income	523	506	237	1,268
3 Total Income (1+2)	17,415	14,815	16,779	66,611
4 Expenses				
(a) Cost of Materials Consumed	3,204	2,689	3,237	11,026
(b) Purchases of Stock-in-Trade	3,306	2,122	2,489	9,514
(c) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	(508)	61	(225)	861
(d) Employee Benefits Expense	3,370	3,160	3,274	12,614
(e) Finance Costs	13	18	15	62
(f) Depreciation and Amortisation Expense	514	537	529	2,143
(g) Other Expenses	3,973	3,728	3,860	15,363
Total Expenses	13,872	12,315	13,179	51,583
5 Profit before exceptional items and tax (3-4)	3,543	2,500	3,600	15,028
6 Exceptional items (Refer Note 3)	-	10,990	-	8,260
7 Profit before tax	3,543	13,490	3,600	23,288
8 Income tax expenses				
a. Current Tax	907	1,748	951	4,969
b. Deferred Tax	7	7	(27)	(5)
Total tax expenses	914	1,755	924	4,964
9 Profit for the period (7-8)	2,629	11,735	2,676	18,324
10 Other Comprehensive Income				
(i) Items that will not be reclassified to Profit or Loss	(2)	(154)	2	(147)
(ii) Income tax relating to items that will not be reclassified to Profit or Loss	1	39	(1)	37
Other Comprehensive Income Net of Tax	(1)	(115)	1	(110)
11 Total Comprehensive Income for the period (9+10)	2,628	11,620	2,677	18,214
12 Paid-up Equity Share Capital (Face Value Rs. 8/- each)	1,323	1,323	1,323	1,323
13 Other Equity				51,730
14 Earnings per Share (of Rs. 8/- each) (not annualised for the quarter):				
(a) Basic (in Rs.)	15.90	70.96	16.18	110.80
(b) Diluted (in Rs.)	15.90	70.96	16.18	110.80

SIGNED FOR IDENTIFICATION
BY 
S R B C & CO LLP
MUMBAI



Notes:

1. The above results have been reviewed and recommended by the Audit Committee at its meeting held on July 24, 2025 and have been approved by the Board of Directors at its meeting held on July 25, 2025.
2. The Company operates in only one reportable business segment i.e. Pharmaceuticals.
3. Exceptional items: (Rs. in Lakhs)

Exceptional Income / (Expenses)	Quarter ended			Year ended
	30-06-2025	31-03-2025	30-06-2024	31-03-2025
	Unaudited	Audited	Unaudited	Audited
Profit on assignment of surplus vacant leasehold land along with built-up structures situated at MIDC, Navi Mumbai	-	12,623	-	9,893
Loss on account of fire incident - Refer note 3(a)	-	(1,633)	-	(1,633)
Total exceptional items	-	10,990	-	8,260

- 3(a) On January 2, 2025, a fire incident occurred at one of the manufacturing blocks of the API plant of the Company located at Plot No. 25/25A, MIDC Land, Thane-Belapur Road, Navi Mumbai – 400703, Maharashtra resulting in an impact on part of the Building, Plant & Machinery, inventories and other assets of the said manufacturing block. All the other manufacturing blocks on the site and buildings housing other departments viz. QC, QA, Engineering, Stores, R&D, etc. are unaffected and are functioning as usual. There was no casualty or loss of human life in this incident. The assets impacted due to the fire incident are adequately covered under an insurance policy. The Company has performed a comprehensive analysis of the estimated loss arising on account of the fire incident for majority of the assets impacted by the fire and accordingly submitted a provisional insurance claim for the estimated loss. The insurance Company has acknowledged the claim and has released two tranches of interim payment aggregating Rs. 850 lakhs. Based on such assessment, the Company has recognised an initial loss of Rs. 2,483 lakhs and a corresponding credit of the two tranches of interim payment of Rs. 850 lakhs resulting in net initial loss of Rs. 1,633 lakhs and the same was disclosed as an exceptional item in the results for the quarter and year ended March 31, 2025. The final amount of the approved claim from the insurance company will be determined based on the completion of the restoration activity of the said block, and additional net gain/loss, if any, would be accounted in subsequent quarters upon finalisation of such claim.
4. Figures of the quarter ended March 31, 2025 are the balancing figure between audited figures in respect of the full financial year and unaudited published year to date figure up to December 31, 2024, which were subject to limited review.



Place : Mumbai
Date : July 25, 2025



For RPG Life Sciences Limited

Ashok Nair
Managing Director
DIN:07906710